Dynavax (DVAX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-90.7M
Depreciation and amortization	1.57M
Amortization of intangible assets
(Gain)/Loss on disposal of assets
Non-cash interest associated with long-term note payable to Symphony Dynamo Holdings LLC
Fair value adjustment of the warrant and contingent liabilities to Symphony Dynamo Holdings LLC
Accretion and amortization of marketable securities	155K
Stock-based compensation expense	10.03M
Accounts receivable
Prepaid expenses and other current assets
Restricted cash and other assets	-99K
Accounts payable	704K
Accrued liabilities and other long term liabilities
Deferred revenues	-2.65M
Net cash used in operating activities
Purchases of marketable securities	-122.03M
Proceeds from maturities of marketable securities
Purchases of property and equipment, net	-6.52M
Net cash provided (used) by investing activities
Proceeds from issuance of common stock, net of issuance costs	0
Proceeds from employee stock purchase plan	616K
Proceeds from exercise of stock options	131K
Proceeds from exercise of warrants
Net cash provided by financing activities
Effect of exchange rate on cash and cash equivalents	104K
Net increase (decrease) in cash and cash equivalents	-21.79M
Cash and cash equivalents at beginning of period	44.81M
Cash and cash equivalents at end of period	23.02M
Disposal of fully depreciated assets	1.16M
Net change in unrealized gain on marketable securities

Entities mentioned with DVAX

View All Entities